AACR convenes conference on health disparities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research, in association with the AACR Minorities in Cancer Research Council, will host a virtual meeting on cancer health disparities Oct. 2-4, 2020.

The Virtual 13th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved aims to advance the understanding of, and ultimately help to eliminate, the disparities that represent a major public health problem in the United States.

The meeting program will include discussion of diversity and inclusion in clinical trials; disparities in cancer risk and treatment among the LGBTQ population; cancer prevention and screening in adolescents and young adults; precision oncology in diverse populations; financial toxicity for cancer patients; the impact COVID-19 has had on patients with cancer; diversifying the cancer research workforce; and more.

The full program is available here. The meeting will build on the themes and data reported in the inaugural AACR Cancer Disparities Progress Report, published Sept. 16, 2020. Read the full report.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login